Matthew J. Rioth

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

Douglas B. Johnson, Garrett M. Frampton, Matthew J. Rioth et al. · Cancer Immunology Research · 2016 · 486 citations · Full text

Engineering, Pd-1 Blockade, Immunology +16

TORC1 Is Essential for NF1-Associated Malignancies

Cory M. Johannessen, Bryan W. Johnson, Sybil M. Genther Williams et al. · Current Biology · 2008 · 200 citations · Full text

Tumor Biology, Medicine, Pathology +5

Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch

Sylvie Giuriato, Sandra Ryeom, Alice C. Fan et al. · Proceedings of the National Academy of Sciences · 2006 · 146 citations · Full text

Immunology, Pathology, Targeted Inactivation +16

Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial

Richard D. Carvajal, Marcus O. Butler, Alexander N. Shoushtari et al. · Nature Medicine · 2022 · 140 citations · Full text

Targeted Deletion of the Calcineurin Inhibitor DSCR1 Suppresses Tumor Growth

Sandra Ryeom, Kwan‐Hyuck Baek, Matthew J. Rioth et al. · Cancer Cell · 2008 · 130 citations · Full text

Medicine, Cancer Biology, Anti-cancer Agent +7